3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Interventions
pembrolizumab
30
Cisplatin
20
Carboplatin
20
Paclitaxel
18
Dexamethasone
14
Pemetrexed
13
Nivolumab
13
Ipilimumab
12
Fluorouracil
11
Cyclophosphamide
11
Gemcitabine
10
Trastuzumab
9
Docetaxel
9
Cytarabine
9
atezolizumab
8
Rituximab
8
Capecitabine
8
daratumumab
7
Doxorubicin
7
zanubrutinib
6
Prednisone
6
Lenalidomide
6
Daunorubicin
6
venetoclax
5
trametinib
5
nilotinib
5
ibrutinib
5
fludarabine
5
dabrafenib
5
Bortezomib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
Filgrastim
×
Clear all
NCT03036488
2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3
Completed
1,174 enrolled
1 FDA